UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018729
Receipt number R000021663
Scientific Title Evaluation of function of respiratory muscles using a fine wire electrodes under hypoxia, hypercapnia, posture changing, drugs and ventilator.
Date of disclosure of the study information 2015/08/19
Last modified on 2020/03/11 08:36:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of function of respiratory muscles using a fine wire electrodes under hypoxia, hypercapnia, posture changing, drugs and ventilator.

Acronym

Evaluation of function of respiratory muscles using a fine wire electrodes.

Scientific Title

Evaluation of function of respiratory muscles using a fine wire electrodes under hypoxia, hypercapnia, posture changing, drugs and ventilator.

Scientific Title:Acronym

Evaluation of function of respiratory muscles using a fine wire electrodes.

Region

Japan


Condition

Condition

COPD, interstitial pneumonia, neuromuscular disease

Classification by specialty

Pneumology Neurology Clinical immunology
Rehabilitation medicine Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to better understanding of the action of respiratory muscles, we measure the EMG activity of respiratory muscles and other ventilatory parameters under hypoxia, hypercapnia, ventilator and respiratory medicine in humans.

Basic objectives2

Others

Basic objectives -Others

To clarify the respiratory muscle activities and coordination of those muscles under hypoxia, hypercapnia, ventilator and respiratory medicine in humans.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

EMG activity of respiratory muscles (i.e. parasternal intercostal, external intercostal, transversus abdominis muscles and so on) obtained by fine wire electrodes.

Key secondary outcomes

Ventilatory parameters (i.e. inspiratory time (TI), expiratory time (TE), total time per breath (TT), frequency of respiration (f), tidal volume (VT) and minute ventilation (VI)), end-tidal CO2 (ETCO2), oxygen saturation values obtained from pulse oximetry (SpO2), and heart rate.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Other

Interventions/Control_1

Pair of fine wire electrodes will be inserted, approximately 10 mm apart, into respiratory muscles (ie. parasternal intercostal muscle, transversus abdominis muscle, and so on) guided by high resolution ultrasound echo graph.
Hypoxia: Subjects rebreathed room air from a 6 L bag until the observed SpO2 was approximately 60% or until the subjects exhibited signs of dyspnea.
Hypercapnia: Subjects rebreathed approximately 7% CO2 balanced O2 gas from a 6 L bag until the observed ETCO2 was approximately 10% or until the subjects exhibited signs of dyspnea.
non invasive positive pressure ventilation (NPPV): Subjects breathed via nose with nasal mask that connected to the NPPV. IPAP will be set between 4 to 20 cmH2O.
Aminophylline: A loading dose of aminophylline 9 mg/kg will be administrated in the first hour, followed by a maintenance dose of 0.75 mg/kg/h. The maintenance dose used is equivalent to a standard clinical therapeutic dosage. Venous blood was sampled and serum theophylline concentrations were measured at 0, 60, 90, and 120 min after the initiation of aminophylline administration.
Short acting beta 2 antagonists: Subjects administrated 20 mcg/min of Salbutamol intravenously and we measured some parameters after 2 hours.
Long acting beta 2 antagonists: Subjects inhaled 100 mcg (4 MDI puff) of Salmeterol and we measured some parameters after 2 hours.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

healthy adult male subject.

Key exclusion criteria

Subjects who have history of pulmonary or cardiovascular or neuromuscular disorders were excluded.
Subjects who have pointed out some abnormality by pre-study evaluation, including pulmonary function tests, electrocardiography and echocardiography.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Masanori
Middle name
Last name Yokoba

Organization

School of Allied Health Sciences, Kitasato University/ Kitasato University Hospital

Division name

Medical Laboratory Sciences/ Pulmonary Medicine

Zip code

194-0001

Address

Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan

TEL

042-778-8111

Email

myoko@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Yokoba

Organization

School of Allied Health Sciences, Kitasato University/ Kitasato University Hospital

Division name

Medical Laboratory Sciences/ Pulmonary Medicine

Zip code

194-0001

Address

Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan

TEL

042-778-8111

Homepage URL


Email

myoko@kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

none


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitasato University Medical Ethics Organization

Address

Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, Japan

Tel

042-778-7756

Email

rinri@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 08 Month 19 Day


Related information

URL releasing protocol

https://www.ncbi.nlm.nih.gov/pubmed/24721495

Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

7

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2012 Year 04 Month 25 Day

Date of IRB

2011 Year 12 Month 26 Day

Anticipated trial start date

2012 Year 05 Month 04 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry

2019 Year 12 Month 31 Day

Date trial data considered complete

2019 Year 12 Month 31 Day

Date analysis concluded

2020 Year 02 Month 29 Day


Other

Other related information



Management information

Registered date

2015 Year 08 Month 19 Day

Last modified on

2020 Year 03 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021663


Research Plan
Registered date File name
2019/09/04 研究実施計画_B0204延長v2.doc

Research case data specifications
Registered date File name

Research case data
Registered date File name